Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-02-27
2000-04-04
Woodward, Michael P.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514832, 514833, 530380, 530385, 424524, 424530, 424533, A61K 3816, A61K 3514
Patent
active
060461616
ABSTRACT:
A method for increasing perfusion in a mammal suffering from cardiogenic shock by administering a perfusion-increasing effective amount of intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.
REFERENCES:
patent: 4598064 (1986-07-01), Walder
patent: 4600531 (1986-07-01), Walder
patent: 4826811 (1989-05-01), Sehgal et al.
patent: 5173426 (1992-12-01), Fischer et al.
patent: 5194590 (1993-03-01), Sehgal et al.
patent: 5334706 (1994-08-01), Przybelshi
patent: 5428007 (1995-06-01), Fischer et al.
patent: 5510464 (1996-04-01), Przybelshi
patent: 5614490 (1997-03-01), Przybelshi
Biro, et al. "The Effect of Hemodilution with Stroma-Free Hemoglobin and Dextran on Collateral Perfusion of Ischemic Myocardium in the Dog" Am. Heart Journal, vol. 99, No. 1, pp. 64-75, 1980.
Feola, et al. "Improved Oxygenation of Ischemic Myocardium by Hemodilution with Stroma-Free Hemoglobin Solution" Chest, vol. 75, No. 3, pp. 369-375, 1979.
Hauck, et al. "Intracoronary Diaspirin Crosslinked Hemoglobin (DCLHb) Infusion During Coronary Balloon Occlusion in Dogs and Pigs" Biomat. Art. Cells and Immob. Biotech., vol. 19, No. 2, abstract, 1991.
McKenzie, et al. "Effects of Intracoronary Infusion of Diaspirin Cross-Linked Hemoglobin (DCLHb) on Cardiac Function and ECG in the Swine" Biomat. Art. Cells and Immob. Biotech., vol. 19, No. 2, abstract, 1991.
McKenzie, et al. "Effects of Diaspirin Cross-Linked Hemoglobin (DCLHb) on Cardiac Function and ECG in the Swine" Biomat. Art. Cells and Immob. Biotech., vol. 20, Nos. 2-4, pp. 683-687, 1992.
Otani, et al. "Reperfusion Injury Induced by Augmented Oxygen Uptake in the Initial Reperfusion Period Possible Efficacy of Extreme Hemodilution" J. Mol. Cell. Cardiol., vol. 17, No. 5, abstract, 1985.
Snyder, et al. "HbXL99.alpha.: A Hemoglobin Derivative that is Cross-Linked Between the .alpha. Subunits is Useful as a Blood Substitute" Proc. Natl. Acad. Sci. USA, vol. 84, pp. 7280-7284, 1987.
Vincent, et al. "Intracoronary Diaspirin Crosslinked Hemoglobin (DCLHb) Infusion During Coronary Balloon Occlusion in Dogs and Pigs" J. Molec. Cell. Cardiol., vol. 23, No. 3 supp., Abstract S.8, 1991.
Baxter International Inc.
Mohamed Abdel A.
Woodward Michael P.
LandOfFree
Use of hemoglobin in the treatment of cardiogenic shock does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of hemoglobin in the treatment of cardiogenic shock, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of hemoglobin in the treatment of cardiogenic shock will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-365006